Jetema Co., Ltd.
Clinical trials sponsored by Jetema Co., Ltd., explained in plain language.
South Korean biopharmaceutical company specializing in botulinum toxin products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New wrinkle filler faces off against market leader Results expected Nov 2026 (estimated)
- New filler JTM102 takes on juvederm in Face-Off trial Results expected Dec 2026 (estimated)
-
New wrinkle filler faces off against market leader
Symptom relief OngoingThis study compares a new injectable filler, JTM104, to the well-known Juvederm for temporarily softening moderate to deep smile lines (nasolabial folds). About 100 adults will receive both treatments in a blinded fashion to see if JTM104 works just as well and is safe. The goal …
Sponsor: Jetema Co., Ltd. • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
New filler JTM102 takes on juvederm in Face-Off trial
Symptom relief OngoingThis study tests a new hyaluronic acid filler called JTM102 against the well-known Juvederm VOLUMA for restoring volume in the mid-face area. About 149 adults aged 19 to 65 with mid-face volume loss will receive both fillers on different sides of their face to compare results. Th…
Sponsor: Jetema Co., Ltd. • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC